Company Encyclopedia
View More
name
Editas Medicine
EDIT.US
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors.
1.946 T
EDIT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking367/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-211.37%E
    • Profit Margin-430.84%E
    • Gross Margin-162.16%E
  • Growth ScoreE
    • Revenue YoY-24.90%E
    • Net Profit YoY5.10%C
    • Total Assets YoY-38.41%E
    • Net Assets YoY-92.34%E
  • Cash ScoreD
    • Cash Flow Margin-23.21%D
    • OCF YoY-24.90%E
  • Operating ScoreD
    • Turnover0.18D
  • Debt ScoreE
    • Gearing Ratio93.33%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CEO O'Neill Files To Sell 7,000 Of Editas Medicine Inc [EDIT]

    CEO O'Neill Gilmore Neil of Editas Medicine Inc filed a Form 144 with the SEC to sell 7,000 shares on December 1, 2025, under a prearranged trading plan (10b5-1). The sale is scheduled for December 3, 2025, through E-TRADE Financial. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing.

    Reuters·
    US
    EDIT
    +2.75%
    Reuters·
    US
    EDIT
    +2.75%

    Editas Medicine (EDIT) Receives a Hold from RBC Capital

    RBC Capital analyst Luca Issi has maintained a Hold rating on Editas Medicine (EDIT) with a price target of $4.00, while the stock closed at $2.52. The analyst consensus for Editas is also a Hold, with a price target of $3.95, indicating a potential upside of 56.75%. Barclays has similarly rated the stock as Hold with a $3.00 price target. Issi has an average return of 6.7% and a success rate of 41.16% on his recommendations.

    Tip Ranks·
    US
    EDIT
    +2.75%
    Tip Ranks·
    US
    EDIT
    +2.75%

    Editas Medicine | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 7.543 M

    LB filings·
    US
    EDIT
    +2.75%
    LB filings·
    US
    EDIT
    +2.75%

    Editas Medicine | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 7.543 M

    LB filings·
    US
    EDIT
    +2.75%
    LB filings·
    US
    EDIT
    +2.75%

    Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials

    Editas Medicine Inc. reported its Q3 2025 financial results, highlighting preclinical data for its candidate EDIT-401, which showed over 90% reduction in LDL cholesterol in non-human primates. The company plans to submit an IND or CTA for EDIT-401 by mid-2026, with initial human data expected by the end of 2026. Editas has extended its cash runway into Q3 2027 and will participate in the Evercore Healthcare Conference on December 2, 2025.

    Reuters·
    US
    EDIT
    +2.75%
    Reuters·
    US
    EDIT
    +2.75%
    © 2025 Longbridge｜Disclaimer